Press Releases April 28, 2026 08:00 AM

electroCore to Present at the Market Movers Investor Summit on May 5, 2026

electroCore to Present at 2026 Market Movers Investor Summit Highlighting Bioelectronic Medicine Advances

By Marcus Reed ECOR
electroCore to Present at the Market Movers Investor Summit on May 5, 2026
ECOR

electroCore, Inc., a Nasdaq-listed bioelectronic medicine company specializing in non-invasive neuromodulation technologies for chronic pain and wellness, announced its participation in the Market Movers Investor Summit on May 5, 2026. Interim President and CFO Joshua Lev will present and meet with investors, providing an opportunity to showcase the company's innovative commercial-stage products such as gammaCore and Quell.

Key Points

  • electroCore will present at the Market Movers Summit on May 5, 2026, with direct investor engagement via one-on-one meetings.
  • The company focuses on bioelectronic medicines, including FDA-cleared non-invasive vagus nerve stimulation devices for chronic pain treatment and wellness.
  • Participation in the summit offers electroCore enhanced visibility among fund managers, family offices, and public/private company executives, potentially aiding capital market activities.

ROCKAWAY, N.J., April 28, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will be participating in the Market Movers Investor Summit at the historic Bank of New York. Joshua Lev, Interim President and CFO, will deliver a presentation and host one-on-one meetings throughout the day.

Event Details:

  • Date: Tuesday, May 5, 2026
  • Company Presentation: 12:20 PM ET
  • Location: 48 Wall Street, New York, NY (The original Bank of New York)

Request an invitation to attend at www.marketmoverssummit.com.

Summary of Market Movers Investor Summit
The 2026 Market Movers Investor Summit begins on May 4th with a kickoff party at the legendary Delmonico’s, followed by a full day of programming on May 5th. The summit brings together public and private company executives, fund managers, and family offices for a focused, high-caliber experience. The agenda includes company presentations and one-on-one meetings, exclusive fireside chats and keynote sessions, a pop-up lunch from the legendary Katz Delicatessen, and a surprise musical guest.

About electroCore, Inc.
electroCore, Inc. is a bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company’s two leading prescription products, gammaCore® non-invasive vagus nerve stimulation (nVNS) and Quell® neurostimulator, treat chronic pain syndromes through non-invasive neuromodulation technology. Additionally, the company commercializes its handheld, and personal use Truvaga™ and TAC-STIM™ nVNS products utilizing bioelectronic technologies to promote general wellness and human performance.

For more information, visit www.electrocore.com.

Contact:
ECOR Investor Relations
(973) 302-9253
[email protected]


Risks

  • Market reaction to investor presentations can be muted if no new groundbreaking data or guidance is shared, limiting immediate stock impact.
  • The evolving competitive landscape in bioelectronic medicine and neuromodulation devices may affect electroCore's commercial growth potential.
  • Regulatory and reimbursement environments remain critical uncertainties for adoption and market penetration of bioelectronic therapies, impacting company revenue.

More from Press Releases

Fiverr Announces First Quarter 2026 Results Apr 29, 2026 Nayax to Report 2026 Q1 Earnings on May 12, 2026 Apr 28, 2026 Xunlei Filed Its Annual Report on Form 20-F for Fiscal Year 2025 Apr 28, 2026 Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Apr 28, 2026 Syntec Optics (Nasdaq: OPTX) Announces Pricing of $20 Million Underwritten Public Offering of Common Stock Apr 28, 2026